Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2019068048) PLACENTA-DERIVED INTERMEDIATE NATURAL KILLER (PINK) CELLS FOR TREATMENT OF GLIOBLASTOMA
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2019/068048 International Application No.: PCT/US2018/053647
Publication Date: 04.04.2019 International Filing Date: 28.09.2018
IPC:
A61K 35/00 (2006.01) ,A61K 35/17 (2015.01) ,A61K 35/50 (2015.01) ,A61K 39/395 (2006.01) ,A61K 9/00 (2006.01) ,A61P 35/00 (2006.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
35
Medicinal preparations containing material or reaction products thereof with undetermined constitution
[IPC code unknown for A61K 35/17]
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
35
Medicinal preparations containing material or reaction products thereof with undetermined constitution
12
Materials from mammals or birds
48
Reproductive organs; Embryos
50
Placenta; Amniotic fluid
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39
Medicinal preparations containing antigens or antibodies
395
Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9
Medicinal preparations characterised by special physical form
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35
Antineoplastic agents
Applicants:
CELULARITY, INC. [US/US]; 33 Technology Drive Warren, New Jersey 07059, US
Inventors:
KANG, Lin; US
ZHANG, Xiaokui; US
VAN DER TOUW, William; US
HARIRI, Robert J.; US
HE, Shuyang; US
Agent:
KNUDSEN, Geoffry T.; US
Priority Data:
62/564,73528.09.2017US
Title (EN) PLACENTA-DERIVED INTERMEDIATE NATURAL KILLER (PINK) CELLS FOR TREATMENT OF GLIOBLASTOMA
(FR) CELLULES NK INTERMÉDIAIRES DÉRIVÉES DU PLACENTA (PINK) POUR LE TRAITEMENT DU GLIOBLASTOME
Abstract:
(EN) Provided herein are methods of treating a subject having a brain tumor, e.g., a glioblastoma by administering to the subject an effective amount of a cell population comprising human placenta-derived natural killer cells. Also provided are methods of suppressing the growth of brain tumor cells comprising contacting the glioblastoma cells with an effective amount of a cell population comprising human placenta-derived natural killer cells. Further provided are compositions comprising subject an effective amount of a cell population comprising human placenta-derived natural killer cells for use in the treatment of a brain tumor in a subject or for use in the manufacture of a medicament for treatment of a brain tumor in a subject.
(FR) La présente invention concerne des procédés de traitement d'un sujet ayant une tumeur cérébrale, par exemple un glioblastome, par l'administration au sujet d'une quantité active d'une population cellulaire comprenant des cellules NK dérivées du placenta humain. La présente invention concerne également des procédés de suppression de la croissance de cellules tumorales cérébrales comprenant la mise en contact des cellules de glioblastome avec une quantité active d'une population de cellules comprenant des cellules NK dérivées du placenta humain. La présente invention concerne en outre des compositions comprenant un sujet d'une quantité active d'une population de cellules comprenant des cellules NK dérivées du placenta humain destinées à être utilisées dans le traitement d'une tumeur cérébrale chez un sujet ou destinées à être utilisées dans la fabrication d'un médicament pour le traitement d'une tumeur cérébrale chez un sujet.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)